Megestrol Acetate NCD Oral Suspension - Par Pharmaceutical: Megestrol Acetate NanoCrystal® Dispersion Oral Suspension, PAR 100.2, PAR-100.21 1 This profile replaces the profile published in Drugs in R&D 2007; 8 (4): 251-4.

Author： Adis International Limited  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.8, Iss.6, 2007-01, pp. : 403-406

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Megestrol Acetate NCD Oral Suspension - Par Pharmaceutical: Megestrol Acetate NanoCrystal® Dispersion Oral Suspension, PAR 100.2, PAR-100.2

By Adis International Limited  

Drugs in R&D, Vol. 8, Iss. 4, 2007-01 ,pp. : 251-254

Adis International

Access to resources Recommend Favorite

Eslicarbazepine Acetate (BIA 2-093): Relative Bioavailability and Bioequivalence of 50 mg/mL Oral Suspension and 200mg and 800mg Tablet Formulations

By Fontes-Ribeiro Carlos  

Drugs in R&D, Vol. 6, Iss. 5, 2005-01 ,pp. : 253-260

Adis International

Access to resources Recommend Favorite

Nomegestrol Acetate/Estradiol: In Oral Contraception

By Yang Lily P.H.   Plosker Greg L.  

Drugs, Vol. 72, Iss. 14, 2012-10 ,pp. : 1917-1928

Adis International

Access to resources Recommend Favorite

Nomegestrol Acetate: Pharmacology, Safety Profile and Therapeutic Efficacy

By Lello Stefano  

Drugs, Vol. 70, Iss. 5, 2010-03 ,pp. : 541-559

Adis International

Access to resources Recommend Favorite

Enhancement of oral absorption of metronidazole suspension in humans

By Idkaidek N.M.   Najib N.M.  

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 50, Iss. 2, 2000-09 ,pp. : 213-216

Elsevier

Access to resources Recommend Favorite